COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In general, all nontopical NSAIDs in doses adequate to reduce inflammation and pain can affect blood pressure levels in both normotensive and hypertensive individuals.
“In general, all nontopical NSAIDs in doses adequate to reduce inflammation and pain can affect BP levels in both normotensive and hypertensive individuals.182”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [182]
Cites
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,737 · see citing works
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,521 · see citing works
Self-citationKearney, P. M., Baigent, C., Godwin, J., Halls, H. J., Emberson, J., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,441 · see citing works
Großer, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,028 · see citing works
Topper, J., Cai, J., Falb, D., & Gimbrone, M. (1996) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.93.19.10417 · Cited by 922 · see citing works
Graham, D. J., Campen, D. H., Hui, R. L., Spence, M. M., Cheetham, C., Levy, G. D., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913 · see citing works
Henry, D. A., Lim, L. L.-Y., Rodriguez, L. A. G., Perez‐Gutthann, S., Carson, J. L., Griffin, M. R., Savage, R. L., Logan, R., Moride, Y., Hawkey, C. J., et al. (1996) · BMJ · doi:10.1136/bmj.312.7046.1563 · Cited by 824 · see citing works
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804 · see citing works
Farkouh, M. E., Kirshner, H. S., Harrington, R. A., Ruland, S. D., Verheugt, F. W. A., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490 · see citing works
Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis
Schafer, A. I. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04050.x · Cited by 370 · see citing works
Hecken, A. V., Schwartz, J. I., Depré, M., Lepeleire, I. D., Dallob, A. L., Tanaka, W. K., Wynants, K., Buntinx, A., Arnout, J., Wong, P. H., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001005 · Cited by 355 · see citing works
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279 · see citing works
Self-citationEffect on platelet aggregation of oral administration of 10 non‐steroidal analgesics to humans
Cronberg, S., Wallmark, E., & Söderberg, I. (1984) · Scandinavian Journal of Haematology · doi:10.1111/j.1600-0609.1984.tb02390.x · Cited by 147 · see citing works
Cardiovascular Effects of the Cyclooxygenase Inhibitors
White, W. B. (2007) · Hypertension · doi:10.1161/01.hyp.0000258106.74139.25 · Cited by 128 · see citing works
Farkouh, M. E., Greenberg, J., Jeger, R. V., Ramanathan, K., Verheugt, F. W. A., Chesebro, J. H., Kirshner, H. S., Hochman, J. S., Lay, C. L., Ruland, S. D., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066001 · Cited by 121 · see citing works
Balancing prostanoid activity in the human vascular system
Flavahan, N. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.01.003 · Cited by 104 · see citing works
Minimising the Adverse Effects of Ketorolac
Reinhart, D. J. (2000) · Drug Safety · doi:10.2165/00002018-200022060-00007 · Cited by 104 · see citing works
Niemi, T., Taxell, C., & Rosenberg, P. H. (1997) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1997.tb04657.x · Cited by 93 · see citing works
Mitchell, J. A., Lucas-Domínguez, R., Vojnovic, I., Hasan, K., Pepper, J., & Warner, T. D. (2006) · The FASEB Journal · doi:10.1096/fj.06-6615com · Cited by 74 · see citing works
Self-citationThe pharmacology of selective inhibition of COX-2
Großer, T. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-08-0444 · Cited by 59 · see citing works
Nomenclature for COX-2 Inhibitors
Vane, J. R., & Warner, T. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02837-3 · Cited by 50 · see citing works
Self-citationNSAIDs, Coxibs, and the Intestine
Hawkey, C. J. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200605001-00013 · Cited by 34 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works
“In general, all nontopical NSAIDs in doses adequate to reduce inflammation and pain can affect BP levels in both normotensive and hypertensive individuals.(182) The results of meta-analyses have indicated that the average increase in mean arterial pressure is highly variable, with a range of reports from 2 to 5 mm Hg.”
BackgroundDiagnosis and Management of Lumbar Spinal Stenosis: A Review
Katz, J. N., Zimmerman, Z. E., Mass, H., & Makhni, M. C. (2022) · JAMA · doi:10.1001/jama.2022.5921 · Cited by 562 · see citing works
Conaghan, P. G. (2011) · Rheumatology International · doi:10.1007/s00296-011-2263-6 · Cited by 414 · see citing works
“Based on clinical evidence and an increased understanding of differences between individual NSAIDs, an alternative concept has been proposed that incorporates the association between increasing dose and NSAID-associated gastrointestinal and cardiovascular risk [77].”
BackgroundNonsteroidal Anti-Inflammatory Drugs and the Kidney
Hörl, W. H. (2010) · Pharmaceuticals · doi:10.3390/ph3072291 · Cited by 298 · see citing works
“In addition, inhibition PG synthesis may cause hypertension, but COX-2 selectivity alone does not define the cardiovascular risk associated with NSAIDs [149].”
BackgroundThe use of lipid-based nanocarriers for targeted pain therapies
Hua, S., & Wu, S. Y. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00143 · Cited by 268 · see citing works
“However, they are associated with numerous interactions with other medications and have serious side effects to the gastrointestinal tract, kidneys, and cardiovascular system (Rittner et al., 2005; Warner and Mitchell, 2008).”
BackgroundRenal adverse effects of nonsteroidal anti-inflammatory drugs
Harirforoosh, S., & Jamali, F. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903311023 · Cited by 260 · see citing works
“First, they inhibit platelet aggregation through inhibition of COX-1 that results in a cardioprotective effect; second, by inhibiting PG synthesis, particularly in the presence of electrolyte retentions, they may cause hypertension [60,96,97].”
BackgroundWarner, T. D., Nylander, S., & Whatling, C. A. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03943.x · Cited by 249 · see citing works
Self-citationVascular COX-2 Modulates Blood Pressure and Thrombosis in Mice
Yu, Y., Ricciotti, E., Scalia, R. G., Tang, S. Y., Grant, G. R., Zhou, Y., Landesberg, G. P., Crichton, I., Wu, W., Puré, E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003787 · Cited by 235 · see citing works
“The detection in observational studies of a cardiovascular hazard from some of the older NSAIDs, such as diclofenac (10, 11), was also used to argue against the mechanistic relevance of selectivity for inhibition of COX-2 (12).”
Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system
Mitchell, J. A., & Kirkby, N. S. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14167 · Cited by 217 · see citing works
“However, as a result of subsequent epidemiology analyses (Warner and Mitchell, 2008; McGettigan and Henry, 2011) and, most recently, the publication of two large clinical cardiovascular outcome studies, SCOT (MacDonald et al., 2017) and PRECISION (Nissen et al., 2016), it is clear that traditional…”
BackgroundResultSelf-citationArmstrong, P., Leadbeater, P. D. M., Chan, M. V., Kirkby, N. S., Jakubowski, J. A., Mitchell, J. A., & Warner, T. D. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04160.x · Cited by 203 · see citing works
Self-citationNSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species
Ghosh, R., Alajbegović, A., & Gomes, A. V. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/536962 · Cited by 197 · see citing works
“An important finding is that not only nonselective NSAIDs lead to the development of hypertension in both normotensive and hypertensive individuals [39], but their use interferes with the antihypertensivemedications except for the calcium channel blockers [40].”
BackgroundCardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Beavers, C. J., Rodgers, J. E., Bagnola, A. J., Beckie, T. M., Campia, U., Palo, K. E. D., Okwuosa, T. M., Przespolewski, E. R., & Sj, D. (2022) · Circulation · doi:10.1161/cir.0000000000001056 · Cited by 168 · see citing works
Anti-inflamatórios não esteroides: Efeitos cardiovasculares, cérebro-vasculares e renais
Batlouni, M. (2010) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2010000400019 · Cited by 135 · see citing works
Ruschitzka, F., Borer, J. S., Krum, H., Flammer, A. J., Yeomans, N. D., Libby, P., Lüscher, T. F., Solomon, D. H., Husni, M. E., Graham, D. Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx508 · Cited by 130 · see citing works
Kirkby, N. S., Lundberg, M. H., Mackenzie, L. S., Leadbeater, P. D. M., Milne, G. L., Potter, C. M. F., Al-Yamani, M., Adeyemi, O., Warner, T. D., & Mitchell, J. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209192109 · Cited by 128 · see citing works
Self-citationFawole, O. A., Ndhlala, A. R., Amoo, S. O., Finnie, J. F., & Staden, J. V. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.03.012 · Cited by 123 · see citing works
Hermanson, D. J., Gamble‐George, J., Marnett, L. J., & Patel, S. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.006 · Cited by 121 · see citing works
“Cardiovascular side effects are exhibited by most NSAIDs, regardless of their selectivity for COX-2, due to a reduction in vascular PGI2 biosynthesis [114, 115].”
BackgroundDefining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity
Knights, K., Mangoni, A. A., & Miners, J. O. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.120 · Cited by 115 · see citing works
Scheiman, J. M., & Hindley, C. E. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.009 · Cited by 110 · see citing works
Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice
Ho, K., Gwee, K., Cheng, Y. K., Yoon, K. H., Hee, H. T., & Omar, A. R. (2018) · Journal of Pain Research · doi:10.2147/jpr.s168188 · Cited by 112 · see citing works
“However, COX2 selectivity varies among c2s-NSAIDs, being greater for lumiracoxib, rofecoxib, etoricoxib, and valdecoxib and comparatively lower for celecoxib.(37) In addition, other potential mechanisms might influence the CV risk of an NSAID.”
BackgroundRationally Designed Multitarget Agents Against Inflammation and Pain
Hwang, S. H., Wecksler, A. T., Wagner, K. M., & Hammock, B. D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130013 · Cited by 109 · see citing works
Huang, Y., Zhang, B., Li, J., Liu, H., Zhang, Y., Zhang, Y., & Liu, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.004 · Cited by 85 · see citing works
Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine
Ahmetaj‐Shala, B., Kirkby, N. S., Knowles, R., Al-Yamani, M., Mazi, S. I., Wang, Z., Tucker, A. T., Mackenzie, L. S., Armstrong, P. C. J., Nüsing, R. M., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.011591 · Cited by 83 · see citing works
“angiotensin levels in blood (GO:0002002); (6) endothelin maturation (GO:0034959); (7)”
BackgroundSelf-citationRole of Shear Stress in Endothelial Cell Morphology and Expression of Cyclooxygenase Isoforms
Potter, C. M. F., Lundberg, M. H., Mackenzie, L. S., Warboys, C. M., Warner, T. D., Berson, R. E., Moshkov, A. V., Gorelik, J., Weinberg, P. D., & Mitchell, J. A. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.214031 · Cited by 83 · see citing works
Self-citationAsghar, W., & Jamali, F. (2014) · Inflammopharmacology · doi:10.1007/s10787-014-0225-9 · Cited by 82 · see citing works
“…issued a warning for the users of selective COX-2 inhibitors as well as non-selective NSAID diclofenac (Antman et al. 2007), thus, generalizing the side effect of NSAIDs beyond the COX-2 selectivity as it was suggested in more recent studies as well (Harirforoosh et al. 2013; Warner et al. 2008).”
ResultKirkby, N. S., Leadbeater, P. D. M., Chan, M. V., Nylander, S., Mitchell, J. A., & Warner, T. D. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04453.x · Cited by 77 · see citing works
Self-citationAtchison, J. W., Herndon, C. M., & Rusie, E. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.s9.1 · Cited by 69 · see citing works
Greco, K. V., Iqbal, A. J., Rattazzi, L., Nalesso, G., Moradi‐Bidhendi, N., Moore, A., Goldring, M. B., Dell’Accio, F., & Perretti, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.09.009 · Cited by 65 · see citing works
“prednisolone (PRED), and naproxen (NAP), a non-selective cyclooxygenase inhibitor [50,51].”
Hamdulay, S., Wang, B., Birdsey, G. M., Ali, F., Dumont, O., Evans, P. C., Haskard, D. O., Wheeler-Jones, C. P. D., & Mason, J. C. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.017 · Cited by 66 · see citing works
Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges
Patrono, C., & Baigent, C. (2009) · Molecular Interventions · doi:10.1124/mi.9.1.8 · Cited by 65 · see citing works
Nguyen, H. T., Vu, T., Vishala, T. C., Polimati, H., & Tatipamula, V. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-72840-8 · Cited by 61 · see citing works
van der Linden, M. W., van der Bij, S., Welsing, P. M. J., Kuipers, E. J., & Herings, R. M. C. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087254 · Cited by 60 · see citing works
In vitro pharmacological evaluation of three Barleria species
Amoo, S. O., Finnie, J. F., & Staden, J. V. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.10.035 · Cited by 59 · see citing works
Kirkby, N. S., Lundberg, M. H., Wright, W. R., Warner, T. D., Paul‐Clark, M. J., & Mitchell, J. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098165 · Cited by 58 · see citing works
“This particularly manifests as an increase in rates of myocardial infarction [1,7,8,9,10], which is consistent with data from animal models showing that COX-2 deletion or inhibition can produce a prothrombotic phenotype [11,12,13].”
ResultSelf-citationCyclooxygenase- and cytochrome P450-derived eicosanoids in stroke
Huang, H., Al‐Shabrawey, M., & Wang, M.-H. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.12.007 · Cited by 57 · see citing works
Anti-inflammatory activity of novel thiosemicarbazone compounds indole-based as COX inhibitors
Jacob, Í. T. T., Gomes, F., de Miranda, M. D. S., de Almeida, S. M. V., Filho, I. J. D. C., Peixoto, C. A., da Silva, T. G., Moreira, D. R. M., de Melo, C. M. L., de Oliveira, J. F., et al. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00221-7 · Cited by 56 · see citing works
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals
Fosbøl, E. L., Køber, L., Torp-Pedersen, C. T., & Gislason, G. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.501331 · Cited by 54 · see citing works
“However, studies have also underlined that the in vitro COX-2 inhibition is relatively high in the usually used doses [13].”
BackgroundHua, S., & Cabot, P. J. (2013) · PubMed · Cited by 51 · see citing works
Blandizzi, C., Tuccori, M., Colucci, R., Fornai, M., Antonioli, L., Ghisu, N., & Tacca, M. D. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.11.004 · Cited by 51 · see citing works
Ozadali‐Sari, K., Özkanlı, F., Jain, S., Rao, P. P. N., & Velázquez‐Martínez, C. A. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.021 · Cited by 50 · see citing works
Tarp, S., Bartels, E. M., Bliddal, H., Furst, D. E., Boers, M., Danneskiold‐Samsøe, B., Rasmussen, M., & Christensen, R. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34644 · Cited by 50 · see citing works
Beaudin, A. E., Pun, M., Yang, C., Nicholl, D. D. M., Steinback, C. D., Slater, D. M., Wynne‐Edwards, K. E., Hanly, P. J., Ahmed, S. B., & Poulin, M. J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000875 · Cited by 45 · see citing works
“Fourth, prostanoid-stable metabolites were assessed in urine as validated markers of systemic prostanoid production,(54) but this provides an integrated measure over the time of urine production, rather than an instantaneous measure of vascular prostanoid concentrations.(64) Fifth, a potential limitation of the sample…”
MethodSaladini, F., Mancusi, C., Bertacchini, F., Spannella, F., Maloberti, A., Giavarini, A., Rosticci, M., Bruno, R. M., Pucci, G., Grassi, D., et al. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.004 · Cited by 47 · see citing works
The search for new COX-2 inhibitors: a review of 2002 – 2008 patents
Ramalho, T. C., Rocha, M. V. J., da Cunha, E. F., & Freitas, M. P. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903059125 · Cited by 47 · see citing works
“PGE2, PGF2, PGD2, prostacyclin (PGI2) and TX A2, interact with specific cell-membrane receptors of the superfamily of G-protein-coupled, playing important roles in many cellular responses and pathophysiologic processes, such as modulation of the inflammatory reaction and its resolution, erosion of cartilage and juxtaa…”
BackgroundAl-Lawati, H., Binkhathlan, Z., & Lavasanifar, A. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.06.025 · Cited by 46 · see citing works
Practice Advisory on the Appropriate Use of NSAIDs in Primary Care
Ho, K., Cardosa, M. S., Chaiamnuay, S., Hidayat, R., Hồ, H. Q. T., Kamil, O., Mokhtar, S. A., Nakata, K., Navarra, S., Nguyen, V. H., et al. (2020) · Journal of Pain Research · doi:10.2147/jpr.s247781 · Cited by 46 · see citing works
Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk
Rovati, G. E., Sala, A., Capra, V., Dahlén, S., & Folco, G. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.007 · Cited by 42 · see citing works
Jiang, H., Zeng, B., Chen, G., Bot, D., Eastmond, S., Elsenussi, S. E., Atkin, S. L., Boa, A. N., & Xu, S. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.014 · Cited by 42 · see citing works
“Fenamates are effective anti-inflammatory agents through COX-1 and COX-2 inhibition, and also inhibit a variety of ion channel activities in many cell types.”
BackgroundInfluentialArmstrong, P. C. J., Kirkby, N. S., Zain, Z. N. M., Emerson, M., Mitchell, J. A., & Warner, T. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020062 · Cited by 41 · see citing works
“Indeed, it may be that other consequences of COX-2 inhibition, notably increases in fluid retention and blood pressure [6,7,9,12,14], provide better mechanistic explanations of the pro-thrombotic effects of drugs that inhibit COX-2.”
BackgroundSelf-citationInflammation: A Mediator Between Hypertension and Neurodegenerative Diseases
Youwakim, J., & Girouard, H. (2021) · American Journal of Hypertension · doi:10.1093/ajh/hpab094 · Cited by 37 · see citing works
Padol, I. T., & Hunt, R. H. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/kep225 · Cited by 37 · see citing works
Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs
Anwar, A., Anwar, I. J., & Delafontaine, P. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.03.006 · Cited by 36 · see citing works
South African botanical resources: A gold mine of natural pro-inflammatory enzyme inhibitors?
Adebayo, S. A., & Amoo, S. O. (2019) · South African Journal of Botany · doi:10.1016/j.sajb.2019.03.020 · Cited by 35 · see citing works
Nanotechnology: A Promising New Paradigm for the Control of Pain
Chakravarthy, K. V., Boehm, F., & Christo, P. J. (2017) · Pain Medicine · doi:10.1093/pm/pnx131 · Cited by 34 · see citing works
Targeting hyaluronan of the endothelial glycocalyx for therapeutic intervention.
Wheeler-Jones, C. P. D., Farrar, C., & Pitsillides, A. A. (2010) · PubMed · Cited by 34 · see citing works
Cadet, C., & Maheu, E. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211022149 · Cited by 34 · see citing works
Bertinaria, M., Shaikh, M. A., Buccellati, C., Cena, C., Rolando, B., Lazzarato, L., Fruttero, R., Gasco, A., Hoxha, M., Capra, V., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200272 · Cited by 32 · see citing works
Indole-based COX-2 inhibitors: A decade of advances in inflammation, cancer, and Alzheimer’s therapy
Shah, M., Parmar, R., Patel, K., & Nagani, A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107931 · Cited by 31 · see citing works
Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain
Angeli, F., Trapasso, M., Signorotti, S., Verdecchia, P., & Reboldi, G. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1540299 · Cited by 31 · see citing works
Bournia, V.-K., Kitas, G. D., Protogerou, A. D., & Sfikakis, P. P. (2016) · Modern Rheumatology · doi:10.1080/14397595.2016.1232332 · Cited by 30 · see citing works
“Consequently, the anti-platelet effect of NSAIDs depends largely on dose and half-life of each individual compound [63].”
BackgroundNSAIDs-dependent adaption of the mitochondria-proteasome system in immortalized human cardiomyocytes
Brandolini, L., Antonosante, A., Giorgio, C., Bagnasco, M., d’Angelo, M., Castelli, V., Benedetti, E., Cimini, A., & Allegretti, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-75394-x · Cited by 31 · see citing works
Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD)
Geusens, P. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902926071 · Cited by 29 · see citing works
“Non-selective NSAIDs inhibit COX-1 and COX-2 and increase the relative risk of perforation, clinically manifest ulcer and bleeding (PUBs) and perforation, 1.”
BackgroundInfluentialColonic anastomoses and non-steroidal anti-inflammatory drugs
Slim, K., Joris, J. L., & Beloeil, H. (2016) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2016.06.011 · Cited by 28 · see citing works
“[6] Warner TD, Mitchell JA.”
BackgroundInfluentialChakraborty, R., Pydi, S. P., Gleim, S., Bhullar, R. P., Hwa, J., Dakshinamurti, S., & Chelikani, P. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00725-12 · Cited by 27 · see citing works
“, ibuprofen) (6, 7) highlight the importance of understanding the G protein specificity of these opposing receptors.”
BackgroundCan drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology
Hinz, B., & Brune, K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.004 · Cited by 26 · see citing works
The Global Burden of Resistant Hypertension and Potential Treatment Options
Buso, G., Rosei, C. A., Lemoli, M., Corvini, F., & Muiesan, M. L. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.51 · Cited by 29 · see citing works
Pharmacological Management of Acute Endodontic Pain
khan, A. W. A., & Diogenes, A. R. (2021) · Drugs · doi:10.1007/s40265-021-01564-4 · Cited by 25 · see citing works
Ruff, C. T., Morrow, D. A., Jarolim, P., REN, F., Contant, C. F., Kaur, A., Curtis, S., Laine, L., Cannon, C. P., & Brune, K. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100880 · Cited by 23 · see citing works
Balancing Risks and Benefits of Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs
Scheiman, J. M. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.03.006 · Cited by 22 · see citing works
“Although there are theoretical reasons why COX-2 selective agents may be prothrombotic, such as decreased production of the vasodilator prostacyclin (which also inhibits platelet activation)with concomitantunimpeded COX-1–mediated production of platelet thromboxane A2, the mechanistic relationship to CV events remains…”
BackgroundPatrício, J. P. H., Barbosa, J., Ramos, R. M. M., Antunes, N. F. P., & de Melo, P. C. S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0052-6 · Cited by 21 · see citing works
Hypertension Update and Cardiovascular Risk Reduction in Physically Active Individuals and Athletes
Oliveira, L., & Lawless, C. E. (2010) · The Physician and Sportsmedicine · doi:10.3810/psm.2010.04.1757 · Cited by 21 · see citing works
Room for improvement: unmet needs in postoperative pain management
Pogatzki-Zahn, E. M., Schnabel, A., & Zahn, P. K. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.30 · Cited by 20 · see citing works
Resistant hypertension: A stepwise approach
Yahr, J., Thomas, G., Calle, J., & Taliercio, J. J. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22046 · Cited by 20 · see citing works
Laufer, S., Greim, C., Luik, S., Ayoub, S. S., & Dehner, F. (2008) · Inflammopharmacology · doi:10.1007/s10787-008-8007-x · Cited by 20 · see citing works
Evidence that diclofenac and celecoxib are thyroid hormone receptor beta antagonists
Zloh, M., Diaz, N. P., Tang, L., Patel, P., & Mackenzie, L. S. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.01.013 · Cited by 20 · see citing works
“Clinical trials revealed the side effects of both pan- and COX-1 sparing NSAIDs led to gastrointestinal damage and cardiovascular complications including myocardial infarction [2,3].”
BackgroundCardiovascular risk associated with nonsteroidal anti-inflammatory drugs
Hermann, M. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0005-5 · Cited by 19 · see citing works
Jain, S., Tran, S., Gendy, M. A. M. E., Kashfi, K., Jurasz, P., & Velázquez‐Martínez, C. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200973j · Cited by 19 · see citing works
Castelli, G., Petrone, A. B., Xiang, J., Shrader, C. D., & King, D. E. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0212-1 · Cited by 18 · see citing works
“One potential mechanism might be NSAID-induced increased blood pressure in both normotensive and hypertensive patients [16, 17].”
BackgroundSommet, A., Grolleau, S., Bagheri, H., Lapeyre‐Mestre, M., & Montastruc, J. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0497-3 · Cited by 18 · see citing works
“Recently, Warmer and Mitchell [ 33 ] suggested that the COX-2 selectivity alone could not explain the cardiovascular risk.”
BackgroundNonsteroidal Anti-Inflammatory Drugs and Their Effects in the Elderly
Park, K. E., Qin, Y., & Bavry, A. A. (2012) · Aging Health · doi:10.2217/ahe.12.6 · Cited by 17 · see citing works
Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk
Minuz, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.042 · Cited by 17 · see citing works
“This finding suggests that the degree of COX inhibition by therapeutic levels of NSAIDs should be considered the major determinant of cardiovascular risk (6,12, 14 ).”
Konzepte zur perioperativen Schmerztherapie
Reichl, S., & Pogatzki-Zahn, E. M. (2009) · Der Anaesthesist · doi:10.1007/s00101-009-1589-x · Cited by 15 · see citing works
Risk Factors for Asymptomatic Echocardiographic Abnormalities that Predict Symptomatic Heart Failure
Coller, J. M., Gong, F. F., McGrady, M., Shiel, L. M., Liew, D., Stewart, S., Owen, A. J., Krum, H., Reid, C. M., Prior, D., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13695 · Cited by 15 · see citing works
“the increased CVD risk and doubling of HF risk by NSAID therapy.(42,43) NSAID therapy increases BP(44); however, the specific association of NSAID therapy with structural abnormality”
BackgroundAhmetaj‐Shala, B., Tesfai, A., Constantinou, C., Leszczynski, R., Chan, M. V., Gashaw, H. H., Galaris, G., Mazi, S. I., Warner, T., Kirkby, N. S., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.161 · Cited by 15 · see citing works
Self-citationChaudakshetrin, P., Penserga, E. G., Lee, D. J., Chen, S., Gill, R. S., Hamid, A., Kumthornthip, W., Liu, Y., Meliala, L., Misbach, H. J., et al. (2012) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2012.01769.x · Cited by 14 · see citing works
Zittel, T., Razavi, D., Papp, A., & Lundberg, K. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e318285bb5a · Cited by 13 · see citing works
“06 CRP, mg/L Preop 12 (6; 18) 11 (7; 15) 0.”
Kirkby, N. S., Tesfai, A., Ahmetaj‐Shala, B., Gashaw, H. H., Sampaio, W. O., Etelvino, G. M., Leão, N. M., Santos, R. A. S., & Mitchell, J. A. (2016) · The FASEB Journal · doi:10.1096/fj.201600647r · Cited by 14 · see citing works
Self-citationThe Use of NSAIDs in the Postoperative Period: Advantage and Disadvantages
(2015) · Journal of Anesthesia & Critical Care Open Access · doi:10.15406/jaccoa.2015.03.00107 · Cited by 14 · see citing works
Hoxha, M., Buccellati, C., Capra, V., Garella, D., Cena, C., Rolando, B., Fruttero, R., Carnevali, S., Sala, A., Rovati, G. E., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.012 · Cited by 14 · see citing works
Analgesic targets: today and tomorrow
Rodger, I. W. (2009) · Inflammopharmacology · doi:10.1007/s10787-009-0006-z · Cited by 13 · see citing works
Immunomodulatory Potential of Diuretics
Bryniarski, P., Nazimek, K., & Marcinkiewicz, J. (2021) · Biology · doi:10.3390/biology10121315 · Cited by 12 · see citing works
Williams, B. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-40196-8.00051-6 · Cited by 12 · see citing works
Montalvo-Jave, E. E., Ortega-Salgado, J. A., Castell, A., Carrasco‐Daza, D., Jay, D., Gleason, R., Muñóz, E., Montalvo-Arenas, C., Hernández-Muñoz, R. E., & Piña, E. (2011) · Transplant International · doi:10.1111/j.1432-2277.2010.01214.x · Cited by 10 · see citing works
Carnevali, S., Buccellati, C., Bolego, C., Bertinaria, M., Rovati, G. E., & Sala, A. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170602083428 · Cited by 10 · see citing works
“Indeed, retrospective analysis showed that CV risk is linked not only to COXIBs but also to first generation antiinflammatory tNSAIDS [44, 77-82], and, in addition, tNSAIDs have also been observed to interfere with the cardio-protective effect of low-dose aspirin, somehow jeopardizing the benefit of their association…”
BackgroundHajimaghsoudi, M., Jalili, M., Mokhtari, M., Nejati, A., Mesbahi, J., & Paydary, K. (2013) · Asian Journal of Sports Medicine · doi:10.5812/asjsm.11411 · Cited by 9 · see citing works
“They concluded that “Use of low risk drugs in low dosage as first line treatment would substantially reduce the morbidity and mortality due to serious gastrointestinal toxicity from these drugs”([19]).”
BackgroundEffects of cox inhibitors on bone and tendon healing
Dimmen, S. (2011) · Acta Orthopaedica · doi:10.3109/17453674.2011.555370 · Cited by 9 · see citing works
Park, D.-H., & Kwon, Y.-U. (2020) · Clinics in Orthopedic Surgery · doi:10.4055/cios.2020.12.1.86 · Cited by 9 · see citing works
Neue Substanzen und Applikationsformen für die postoperative Schmerztherapie
Pogatzki-Zahn, E. M., & Zahn, P. K. (2008) · Der Schmerz · doi:10.1007/s00482-008-0665-5 · Cited by 9 · see citing works
Potential role of NSAIDs loaded nano-formulations to treat inflammatory diseases
Zahoor, I., Bala, R., Wani, S. N., Chauhan, S., Madaan, R., Kumar, R., Hakeem, K. R., & Malik, I. A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01644-x · Cited by 8 · see citing works
“Consequently, the encapsulation of NSAIDs does not alter their COX-1/COX-2 selectivity however, it modifies the in vivo biodistribution of the encapsulated drug, preventing its accumulation in tissues susceptible to NSAID-related adverse effects (Warner and Mitchell 2008).”
- Authors
- Warner, T. D., & Mitchell, J. A.
- Affiliations
- Queen Mary University of London (GB)
- Royal Brompton Hospital (GB)
- Corresponding author
- Warner, Timothy D
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 371
- Issue
- 9608
- Pages
- 270-273
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2164162242
- Cited by
- 166
- References
- 22
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 8 · 2019: 4 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 7 · 2014: 12 · 2013: 9 · 2012: 16
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- COX-2 selectivity, nonsteroidal anti-inflammatory drugs, cardiovascular risk, thrombosis risk, gastrointestinal risk, cyclooxygenase inhibition, cyclooxygenase-1, cyclooxygenase-2, etoricoxib, rofecoxib, celecoxib, lumiracoxib, drug safety, cardiovascular adverse events, gastrointestinal adverse effects, American Heart Association guidelines
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Dose-Response Relationship, Drug, Gastrointestinal Diseases, Humans, Myocardial Infarction, Risk Factors, Thrombosis, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
